Latest research on MK-0518

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. [Wikipedia]

MK-0518 interactions

The HARRT regiments were based on 2 reverse transcriptase inhibitors (mainly Combivir, Truvada, or Kivexa) and either a nonnucleoside reverse transcriptase inhibitor (Efaviranze) or a boosted protease inhibitor (mainly Kaletra, boosted Atazanavir, or boosted Darunavir) or an integrase inhibitor (Isentress). [source, 2016]
PubMed and EMBASE search terms were “HIV-1 [mesh] OR HIV infections [mesh] NOT pregnancy [mesh] AND ((dolutegravir OR GSK1349572) OR (Efavirenz OR Sustiva OR Stocrin OR DMP-266) OR (raltegravir OR Isentress OR MK-0518) OR (elvitegravir OR GS-9137 OR JTK-303) OR (rilpivirine OR Edurant OR TMC 278) OR (Darunavir OR Prezista OR TMC-114) OR (atazanavir OR Reyataz OR BMS-232632) OR (lopinavir OR ABT-378 OR Aluviran OR Koletra OR Kaletra) OR (Atripla OR Quad OR Stribild OR Eviplera OR Complera))”. [source, 2014]
aDrugs with sales above $100 million in 2010: Atripla ($2927 million), Truvada ($2746 million), Reyataz ($1479 million), Kaletra ($1255 million), Isentress ($1090 million), Prezista ($888 million), Epzicom ($858 million), Combivir ($561 million), Norvir ($344 million), Sustiva ($315 million), Viramune ($295 million), Intelence ($243 million), Trizivir ($223 million), Crixivan ($206 million), Epivir ($178 million), Ziagen ($159 million), Selzentry ($124 million), Viracept ($112 million); values from EvaluatePharma [23]. [source, 2013]
Clinical formulations of these drugs in tablet form (Maraviroc (Selzentry) 150 mg, Pfizer Labs; Raltergravir (Isentress) 400 mg, Merck & Co) were freshly dissolved in distilled water each day prior to oral gavage. [source, 2010]
The availability of ARV drugs began in 1987 with the zidovidine and the latest ones to be approved in 2007 are the Maraviroc [8] and Raltegravir [9] potassium marketed as Selzentry (Pfizer) and Isentress (Merck) respectively. [source, 2010]
• Merck and Company announced it would cut its price of Stocrin (Efavirenz) in Mexico by 40% from 777 pesos per patient monthly to 468 pesos (roughly from US $77.50 to US $46), and on Isentress (raltegravir) by 30% from 9.05 pesos to 6.85 pesos per patient monthly (approximately US $903 to US $683). [source, 2009]
Therefore, the development or availability of new drugs such as Fuzeon, the HIV-1 integrase inhibitor raltegravir (MK-0518) (Grinsztejn et al. 2007) and the CCR5 antagonist maraviroc (Stephenson, 2007) that remain active against drug resistant virus is essential for the continuing success of HAART (Yeni, 2006). [source, 2007]